Get started
Author

Antoine Angelergues

Observed names: A. Angelergues, Angelergues, Antoine
Observed institutions: Universitat Autònoma de Barcelona, Centre National de la Recherche Scientifique, Inserm, University of California, Los Angeles, Université Paris Cité, Aix-Marseille Université, Universitair Ziekenhuis Leuven, Institut Necker Enfants Malades, Sorbonne Paris Cité, Assistance Publique – Hôpitaux de Paris, Hospital Universitario 12 De Octubre, Hôpital Européen Georges-Pompidou, Hôpital Saint-Antoine, Groupe Hospitalier Diaconesses Croix Saint-Simon, Centre Hospitalier Universitaire de Liège, Hôpital des Diaconesses, Hôpital Saint-Louis, Institut Paoli-Calmettes, Université Paris Diderot, Université Paris Descartes, Université Pierre-et-Marie-Curie, University College London, University of Oklahoma Health Sciences Center, Institut Curie, KU Leuven
ORCID: 0009-0005-4876-918X
Observed ORCID: 0009-0005-4876-918X
OpenAlex ID: A5050807694
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer
2023 · Kathleen N. Moore, Antoine Angelergues, et al. · New England Journal of Medicine · 554
PDF
Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial
2023 · Ana Oaknin, Laurence Gladieff, et al. · The Lancet · 267
PDF
Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
2024 · Ignace Vergote, Antonio González-Martín, et al. · New England Journal of Medicine · 224
PDF
Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression.
2023 · Kathleen N. Moore, Antoine Angelergues, et al. · Journal of Clinical Oncology · 56
Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer
2014 · Antoine Angelergues, Denis Maillet, et al. · European Journal of Cancer · 55
Neoadjuvant and adjuvant pembrolizumab in advanced high-grade serous carcinoma: the randomized phase II NeoPembrOV clinical trial
2024 · Isabelle L. Ray-Coquard, Aude-Marie Savoye, et al. · Nature Communications · 33
Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor–Targeted Agents
2018 · Antoine Angelergues, Eleni Efstathiou, et al. · Clinical Genitourinary Cancer · 22
Prognostic factors of survival in patients with metastatic castration resistant prostate cancer (mCRPC) treated with cabazitaxel: Sequencing might matter.
2013 · Antoine Angelergues, Denis Maillet, et al. · Journal of Clinical Oncology · 22
Duration of response to androgen-deprivation therapy (ADT) and efficacy of secondary hormone therapy, docetaxel (D), and cabazitaxel (C) in metastatic castration-resistant prostate cancer (mCRPC).
2014 · Antoine Angelergues, Denis Maillet, et al. · Journal of Clinical Oncology · 20
FOLFIRI Plus Durvalumab With or Without Tremelimumab in Second-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: The PRODIGE 59-FFCD 1707-DURIGAST Randomized Clinical Trial
2024 · David Tougeron, Laetitia Dahan, et al. · JAMA Oncology · 17
PDF
In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study.
2023 · Isabelle Laure Ray-Coquard, Marie-Christine Kaminsky-Forrett, et al. · Journal of Clinical Oncology · 17
PDF
Safety and efficacy of 2‐weekly cabazitaxel in metastatic castration‐resistant prostate cancer
2017 · Alice Clément‐Zhao, Marie Auvray, et al. · British Journal of Urology · 17
Circulating tumor DNA strongly predicts efficacy of chemotherapy plus immune checkpoint inhibitors in patients with advanced gastro-esophageal adenocarcinoma
2025 · David Tougeron, Christophe Louvet, et al. · Communications Medicine · 15
PDF
VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)
2023 · A. Oaknin, L. Gladieff, et al. · Annals of Oncology · 12
PDF
Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial
2026 · Isabelle Ray-Coquard, Marie-Christine Kaminsky-Forrett, et al. · Nature Communications · 11
PDF
Retrospective registry evaluating the PSA flare phenomenon with cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC).
2013 · Antoine Angelergues, Florence Mercier, et al. · Journal of Clinical Oncology · 11
Efficacy of cabazitaxel and its relationship with predictors of poor response to second hormonal therapies (2d HT) in metastatic castration-resistant prostate cancer (mCRPC).
2013 · Stephane Oudard, Florence Mercier, et al. · Journal of Clinical Oncology · 10
Previous enzalutamide therapy and response to subsequent taxane therapy in metastatic castration-resistant prostate cancer.
2015 · Marco Gizzi, Giulia Baciarello, et al. · Journal of Clinical Oncology · 6
Prospective and Comparative Evaluation of the Toxicity of Adjuvant Concurrent Chemoradiotherapy After Neoadjuvant Chemotherapy for Breast Cancer
2012 · Virginie Marchand, Antoine Angelergues, et al. · American Journal of Clinical Oncology · 6
Final overall survival analysis among patients with folate receptor alpha-positive, platinum-resistant ovarian cancer treated with mirvetuximab soravtansine versus investigator's choice chemotherapy in phase II MIRASOL (GOG-3045/ENGOT-ov55) study
2025 · Toon Van Gorp, Antoine Angelergues, et al. · Gynecologic Oncology · 5
The PRODIGE 59-DURIGAST trial: A randomized phase II study evaluating FOLFIRI plus durvalumab and FOLFIRI plus durvalumab plus tremelimumab in second-line treatment of patients with advanced gastric or gastro-esophageal junction adenocarcinoma.
2022 · David Tougeron, Laetitia Dahan, et al. · Journal of Clinical Oncology · 5
Human and murine prostate basal/stem cells are not direct targets of prolactin
2015 · Lucila Sackmann-Sala, Antoine Angelergues, et al. · General and Comparative Endocrinology · 5
Cabazitaxel—the taxane of choice in the new mCRPC landscape?
2014 · Stéphane Oudard, Antoine Angelergues · Nature Reviews Urology · 5
34O ROCSAN: A multicentric randomized phase II/III evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of endometrial/ovarian carcinosarcoma after at least one line of platinum-based chemotherapy – Preliminary results
2024 · I.L. Ray-Coquard, A. Bellesoeur, et al. · ESMO Open · 4
PDF
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2022–2023 : Prise en charge du cancer de l'endomètre métastatique et/ou en rechute
2023 · Jérôme Alexandre, Marie-Aude Le Frère-Belda, et al. · Bulletin du Cancer · 4
PDF
Works count: 63
Citation count: 1,451
H-index: 13
I10-index: 17
Year
Topic
Type